These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23209818)

  • 21. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome.
    Shichiri M; Yoshida Y; Ishida N; Hagihara Y; Iwahashi H; Tamai H; Niki E
    Free Radic Biol Med; 2011 Jun; 50(12):1801-11. PubMed ID: 21447382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
    Kazim SF; Blanchard J; Bianchi R; Iqbal K
    Sci Rep; 2017 Apr; 7():45561. PubMed ID: 28368015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Size does not always matter: Ts65Dn Down syndrome mice show cerebellum-dependent motor learning deficits that cannot be rescued by postnatal SAG treatment.
    Gutierrez-Castellanos N; Winkelman BH; Tolosa-Rodriguez L; Devenney B; Reeves RH; De Zeeuw CI
    J Neurosci; 2013 Sep; 33(39):15408-13. PubMed ID: 24068809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome.
    Rueda N; Flórez J; Martínez-Cué C
    Behav Brain Res; 2008 Apr; 188(2):355-67. PubMed ID: 18178265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
    Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
    Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
    Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R
    Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice.
    Rueda N; Vidal V; García-Cerro S; Puente A; Campa V; Lantigua S; Narcís O; Bartesaghi R; Martínez-Cué C
    J Nutr; 2020 Sep; 150(9):2478-2489. PubMed ID: 32729926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.
    Busciglio J; Pelsman A; Helguera P; Ashur-Fabian O; Pinhasov A; Brenneman DE; Gozes I
    Curr Pharm Des; 2007; 13(11):1091-8. PubMed ID: 17430172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
    Sari Y; Gozes I
    Brain Res Rev; 2006 Aug; 52(1):107-18. PubMed ID: 16488478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats.
    Kumral A; Yesilirmak DC; Sonmez U; Baskin H; Tugyan K; Yilmaz O; Genc S; Gokmen N; Genc K; Duman N; Ozkan H
    Brain Res; 2006 Oct; 1115(1):169-78. PubMed ID: 16938277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide-mediated protection from ethanol-induced neural tube defects.
    Chen SY; Charness ME; Wilkemeyer MF; Sulik KK
    Dev Neurosci; 2005; 27(1):13-9. PubMed ID: 15886480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide antagonists of ethanol inhibition of l1-mediated cell-cell adhesion.
    Wilkemeyer MF; Menkari CE; Spong CY; Charness ME
    J Pharmacol Exp Ther; 2002 Oct; 303(1):110-6. PubMed ID: 12235240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.
    Wilkemeyer MF; Chen SY; Menkari CE; Brenneman DE; Sulik KK; Charness ME
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8543-8. PubMed ID: 12808140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of alcohol-induced learning deficits in fetal alcohol syndrome mediated through NMDA and GABA receptors.
    Toso L; Poggi SH; Roberson R; Woodard J; Park J; Abebe D; Spong CY
    Am J Obstet Gynecol; 2006 Mar; 194(3):681-6. PubMed ID: 16522397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
    Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
    Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.
    Spong CY; Abebe DT; Gozes I; Brenneman DE; Hill JM
    J Pharmacol Exp Ther; 2001 May; 297(2):774-9. PubMed ID: 11303069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.